Filter Results:
(483)
Show Results For
- All HBS Web (483)
- Faculty Publications (186)
Show Results For
- All HBS Web (483)
- Faculty Publications (186)
- September 2019
- Case
Celgene: Business Development and Distributed Research
By: Peter Barrett and Kareem Reda
This case looks at the deal-making process between Celgene, a large publicly traded pharmaceutical company, and Agios, an early-stage biotech company. The framework of a potential deal is explored and the potential road-blocks to Agios’ profitability are discussed. ... View Details
Keywords: Negotiation Deal; Alliances; Collaborative Innovation and Invention; Research; Pharmaceutical Industry; Pharmaceutical Industry
Barrett, Peter, and Kareem Reda. "Celgene: Business Development and Distributed Research." Harvard Business School Case 620-014, September 2019.
- Web
Research - Global
Research September 2025 Article Journal of Development Economics Using Satellites and Phones to Evaluate and Promote Agricultural Technology Adoption: Evidence from Smallholder Farms in India By: Shawn Cole , Tomoko Harigaya, Grady... View Details
- 22 Apr 2009
- Working Paper Summaries
Where is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location
- 05 Jul 2006
- Working Paper Summaries
Do Managers’ Heuristics Affect R&D Performance Volatility? A Simulation Informed by the Pharmaceutical Industry
- March 2024
- Article
Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act
By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti
The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that... View Details
Keywords: Policy; Government Legislation; Health Care and Treatment; Negotiation; Price; Pharmaceutical Industry
Vogel, Matthew, Pragya Kakani, Amitabh Chandra, and Rena M. Conti. "Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act." Nature Biotechnology 42, no. 3 (March 2024): 406–412.
- Web
Research - Health Care
Faculty & Research Research November 2024 Teaching Material Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams By: Debora L. Spar and Julia M. Comeau Teaching Note for HBS Case No.... View Details
- October 2023 (Revised May 2024)
- Case
Thermo Fisher Scientific: Foray into Contract Research
By: Satish Tadikonda, William Marks and Kevin Emancipator
After publicly declaring that they would not enter the contract research organization (CRO) business in 2017, Thermo Fisher purchased Pharmaceutical Product Development (PPD), one of the biggest players in the CRO space, in 2021. Much had changed in the intervening... View Details
Keywords: Mergers and Acquisitions; Customer Focus and Relationships; Corporate Strategy; Organizational Change and Adaptation; Biotechnology Industry
Tadikonda, Satish, William Marks, and Kevin Emancipator. "Thermo Fisher Scientific: Foray into Contract Research." Harvard Business School Case 824-073, October 2023. (Revised May 2024.)
- December 2022
- Article
The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies
By: Pragya Kakani, Michael Chernew and Amitabh Chandra
Context: To what extent does pharmaceutical revenue growth depend on new medicines versus increasing prices for existing medicines? Moreover, does using list prices, as is commonly done, instead of prices net of confidential rebates offered by manufacturers, which are... View Details
Kakani, Pragya, Michael Chernew, and Amitabh Chandra. "The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies." Journal of Health Politics, Policy and Law 47, no. 6 (December 2022): 629–648.
- August 1995 (Revised June 1997)
- Case
Hillcrest Research Associates, Inc.
Hillcrest designs and administers testing procedures for drugs to determine whether they pass FDA specifications. As the company grows, it encounters problems with information technology and with the clinical research associates, who feel pressured to report more... View Details
Keywords: Growth Management; Information Technology; Health Testing and Trials; Pharmaceutical Industry
Barnes, Louis B. "Hillcrest Research Associates, Inc." Harvard Business School Case 496-021, August 1995. (Revised June 1997.)
- March 2023 (Revised March 2025)
- Case
Close Concerns: Diabetes Research and Advocacy
By: Regina Herzlinger and Brian L. Walker
Diagnosed with diabetes at the age of 18, Kelly Close understood the importance of balancing consistency and iteration. This principle had also informed her professional work, which started with a rapid promotion from financial analyst at Goldman Sachs to an analyst... View Details
- 18 Jun 2001
- Research & Ideas
When In-House Research Isn’t Enough
For many decades, corporate research and development has been pretty much an "inside job." The road to innovative new products and services began and ended with a company's internal R&D. But according to HBS assistant... View Details
Keywords: by Jim Aisner
- Article
Trends and Predictors of Biomedical Research Quality, 1990–2015: A Meta-Research Study
By: Maryaline Catillon
Keywords: Biomedical Research; R&D; Innovation; Technology; Drug Trials; RCT; Health; Healthcare; Health Care And Treatment; Health Care Policy; Innovation and Invention; Innovation Strategy; Research and Development; Technological Innovation; Pharmaceutical Industry; Pharmaceutical Industry
Catillon, Maryaline. "Trends and Predictors of Biomedical Research Quality, 1990–2015: A Meta-Research Study." BMJ Open 9, no. 9 (September 2019).
- January 2001 (Revised July 2003)
- Case
Pharmacyclics: Financing Research & Development
By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more... View Details
Keywords: Valuation; Cash Flow; Financing and Loans; Business Startups; Financial Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Baker, Malcolm P., Richard S. Ruback, and Aldo Sesia. "Pharmacyclics: Financing Research & Development." Harvard Business School Case 201-056, January 2001. (Revised July 2003.)
- 15 Jan 2019
- First Look
New Research and Ideas, January 15, 2019
Human Decision Processes Seeker Beware: The Interpersonal Costs of Ignoring Advice By: Blunden, Hayley, Jennifer M. Logg, Alison Wood Brooks, Leslie John, and Francesca Gino Abstract—Prior advice research has focused on understanding when... View Details
Keywords: Dina Gerdeman
- Web
Strategy - Faculty & Research
2019, through a partnership with Western pharmaceutical company DrugCo, Daiichi Sankyo developed Enhertu®, an antibody-drug conjugate (ADC) that was highly successful in the global oncology market. Subsequently, Daiichi Sankyo expanded... View Details
- September 2014
- Case
Pfizer's Centers for Therapeutic Innovation (CTI)
By: Gary Pisano, James Weber and Kait Szydlowski
In 2010, Pfizer established four small research units in New York, Boston, San Francisco, and San Diego located close to several premier Academic Medical Centers (AMCs), or hospitals with adjoining medical schools. The goal of these units was to redesign collaboration... View Details
Keywords: Drug Development; Academic Collaboration; Research And Development; Innovation; Translational Research; Management; Operations; Problems and Challenges; Research; Science; Information Technology; Strategy; Pharmaceutical Industry; Pharmaceutical Industry; North and Central America; Europe; Asia
Pisano, Gary, James Weber, and Kait Szydlowski. "Pfizer's Centers for Therapeutic Innovation (CTI)." Harvard Business School Case 615-024, September 2014.
- 01 Jun 2023
- News
Research Brief: The Best Medicine
As it turns out, innovation doesn’t benefit everyone equally, and a new study tries to understand how that plays out in the pharmaceutical R&D process in the United States. “The numbers are striking,” says Associate Professor Joshua... View Details
- 01 Sep 2023
- News
Research Brief: Making Way for Moonshots
Josh Krieger (Courtesy subject) Josh Krieger (Courtesy subject) Many innovations in modern medicine have come about due to cutting-edge drugs—advances that required both a scientific leap and a willingness to take risks. And while most View Details
Keywords: Jen McFarland Flint
- 02 Aug 2004
- Research & Ideas
Health Care Research and Prospects
As is clear to anyone who pays medical insurance premiums or has undergone any kind of medical procedure, the business of health care is an expensive one. The technology is expensive. The research is expensive. The services are expensive.... View Details
- 16 Jan 2018
- First Look
First Look at New Research and Ideas, January 16, 2018
https://www.hbs.edu/faculty/Pages/item.aspx?num=53705 Developing Novel Drugs By: Krieger, Joshua, Danielle Li, and Dimitris Papanikolaou Abstract—We analyze firms' decisions to invest in incremental and radical innovation, focusing specifically on View Details
Keywords: Sean Silverthorne